35 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
4
Ending by 2030
Jan 2027
Next term end
20
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Aug 2028 · High confidence
Also notable
Ends Jun 2033 · Medium confidence
Also notable
Ends Mar 2038 · High confidence
Also notable
Ends Oct 2037 · High confidence
Also notable
Ends no later than Oct 2036 · Medium confidence
Also notable
Ends Mar 2028 · High confidence
Also notable
Ends Aug 2036 · High confidence
Also notable
Ends Aug 2036 · High confidence
Liposomes Useful for Drug Delivery
US 8,147,867
The most cited patent in this portfolio, cited by 148 later US patents, top 5% of utility patents granted in 2012 in our data. Protection runs to 2028.
Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
US 9,492,442
Cited by 26 later US patents, top 25% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
Chimeric Neurotoxins
US 11,434,265
Cited by 9 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2038.
Cellular Vamp Cleavage Assay
US 11,193,931
Cited by 22 later US patents, top 10% of utility patents granted in 2021 in our data. Protection runs to 2037.
Stabilizing Camptothecin Pharmaceutical Compositions
US 10,993,914
Cited by 7 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2036. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Pharmaceutical Composition Comprising Botulinum, a Non Ionic Surfactant, Sodium Chloride and Sucrose
US 9,125,804
Cited by 39 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2028.
Combination Therapy for Cancer Treatment
US 9,895,365
Cited by 24 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2036.
Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
US 11,344,552
A family of 6 related applications built on the 2022 grant. Protection runs to 2036.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 8, 2027The maintenance fee for Pharmaceutical Composition Comprising Botulinum, a Non Ionic Surfactant, Sodium Chloride and Sucrose (US 9,125,804) comes due Mar 8, 2027. Unpaid by Sep 8, 2027, it lapses early.
- 1 fee due Apr 29, 2027The maintenance fee for Stabilizing Camptothecin Pharmaceutical Compositions (US 10,456,360) comes due Apr 29, 2027. Unpaid by Oct 29, 2027, it lapses early.
- 1 fee due May 19, 2027The maintenance fee for Combination Therapy for Cancer Treatment (US 10,478,428) comes due May 19, 2027. Unpaid by Nov 19, 2027, it lapses early.
- 1 fee due Jun 19, 2027The maintenance fee for Combination Therapy for Cancer Treatment (US 11,844,795) comes due Jun 19, 2027. Unpaid by Dec 20, 2027, it lapses early.
- 2 fees due Nov 7 to 17, 2027 · next Nov 7
Recent changes
- Sep 18Assignment recorded on 1 record: Pons, Laurent and 2 others to Ipsen Biopharm Limited Recorded Sep 18, 2026, executed May 28, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76507, frame 493.
What they patent
The largest of its 20 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan | 8 in force | to Feb 2034 |
| Stabilizing Camptothecin Pharmaceutical Compositions | 3 in force | to May 2037 |
| Combination Therapy for Cancer Treatment | 3 in force | to Aug 2036 |
| Liposomes Useful for Drug Delivery | 3 in force | to Nov 2029 |
| Cellular Vamp Cleavage Assay | 2 in force | to Apr 2040 |
| Chimeric Neurotoxins | 2 in force | to Apr 2039 |
| Treatment of Brain Damage | 1 in force | to Dec 2042 |
| Clostridial Neurotoxins Comprising an Exogenous Activation Loop | 1 in force | to Jul 2042 |
| Method of Purifying Botufinum Toxin | 1 in force | to Apr 2042 |
| Suppression of Bone Cancer-induced Allodynia | 1 in force | to Jun 2041 |
| Therapeutic and Cosmetic Uses of Botulinum Neurotoxin Serotype E | 1 in force | to Jun 2041 |
| Evolution of Bont Peptidases | 1 in force | to Jan 2040 |
| Non-Neuronal Snare-Cleaving Botulinum Neurotoxins | 1 in force | to Jan 2039 |
| Production of Activated Clostridial Neurotoxins | 1 in force | to Aug 2037 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,329,213 | Liposomes Useful for Drug Delivery In force · High confidence | In force | High confidence | |
| US 9,125,804 | Pharmaceutical Composition Comprising Botulinum, a Non Ionic Surfactant, Sodium Chloride and Sucrose In force · High confidence | In force | High confidence | |
| US 8,147,867 | Liposomes Useful for Drug Delivery In force · High confidence | In force | High confidence | |
| US 8,658,203 | Liposomes Useful for Drug Delivery to the Brain In force · High confidence | In force | High confidence | |
| US 9,339,497 | Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan In force · High confidence | In force | High confidence | |
| US 9,364,473 | Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan In force · Medium confidence | In force | Medium confidence | |
| US 9,452,162 | Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan In force · Medium confidence | In force | Medium confidence | |
| US 9,492,442 | Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan In force · Medium confidence | In force | Medium confidence | |
| US 9,717,724 | Methods for Treating Pancreatic Cancer Using Combination Therapies In force · Low confidence | In force | Low confidence | |
| US 10,980,795 | Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 35: 25 patents ended · 40 applications pending · 67 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.